Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial

Published:2022-11 Issue:11 Volume:23 Page:1378-1388
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Long Georgina V,Luke Jason J,Khattak Muhammad A,de la Cruz Merino Luis,Del Vecchio Michele,Rutkowski Piotr,Spagnolo Francesco,Mackiewicz Jacek,Chiarion-Sileni Vanna,Kirkwood John M,Robert Caroline,Grob Jean-Jacques,de Galitiis Federica,Schadendorf Dirk,Carlino Matteo S,Mohr Peter,Dummer Reinhard,Gershenwald Jeffrey E,Yoon Charles H,Wu Xi Lawrence,Fukunaga-Kalabis Mizuho,Krepler Clemens,Eggermont Alexander M M,Ascierto Paolo A

Funder

Merck

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Oncology

Reference19 articles.

1. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

2. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

3. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma;Long;N Engl J Med,2014

4. Targeted agents and immunotherapies: optimizing outcomes in melanoma;Luke;Nat Rev Clin Oncol,2017

5. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma;Long;N Engl J Med,2017

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of anti PD-1 therapy in children and adolescent melanoma patients (MELCAYA study);European Journal of Cancer;2024-11

2. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit;Critical Reviews in Oncology/Hematology;2024-10

3. Advances in Adjuvant and Neoadjuvant Therapy for Melanoma;Hematology/Oncology Clinics of North America;2024-10

4. Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma;Cancer Treatment Reviews;2024-09

5. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial;European Journal of Cancer;2024-09